Wockhardt and its subsidiaries Wockhardt UK Holdings and CP Pharmaceuticals have settled an ongoing litigation with Teva Pharmaceuticals, US, in the High Court of London. The litigation, relating to the supply contract for Trisenox, is over the price charged by CP Pharmaceuticals. The Wockhardt firms have agreed to waive their claim for outstanding trade receivables worth €20 million and further paid €23 million to Teva and Cephalon (its affiliate) for a final settlement.
What to watch. Wockhardt ends dispute with Teva
Published on
June 22, 2017 16:08